Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
In a recent study, scientists led by Professor Stefan Müller from Goethe University's Institute of Biochemistry II investigated a specific form of blood cancer known as acute myeloid leukemia, or AML.
The concept of irreversible inhibitors binding permanently to a target protein has garnered growing interest for potential applications in drug development.
Trans-vaccenic acid (TVA), a long-chain fatty acid found in meat and dairy products from grazing animals such as cows and sheep, improves the ability of CD8+ T cells to infiltrate tumors and kill cancer cells, according to a new study by researchers from the University of Chicago.
Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated.
Some patients with myelodysplastic syndromes, like acute myeloid leukemia, benefit from a chemotherapy drug called decitabine that stunts cancer growth. But many others are resistant to decatibine's effects or become resistant over time.
A multicenter study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine shows how interactions between tumor cells and immune components of the microenvironment can impact treatment responses and outcomes in patients newly diagnosed with multiple myeloma who undergo combination treatments that include targeted immunotherapy.
In the late 1970s, the link between the c-Src gene and cancer was unveiled, marking the identification of the inaugural oncogene.
A new, bio-inspired drug restores the effectiveness of immune cells in fighting cancer, a team led by researchers at The University of Texas at Austin has found.
Using laboratory-grown cells from humans and genetically engineered mice, scientists at Johns Hopkins Medicine say they have evidence that modifying a specific protein in immune white blood cells known as CD8+ T cells can make the cells more robust, potentially opening the door for better use of people's own immune system T cells to fight cancer.
Deep inside our cells-;each one complete with an identical set of genes-;a molecular machine known as PRC2 plays a critical role in determining which cells become heart cells, versus brain or muscle or skin cells.
The memory of the immune system depends on distinctive epigenetic traits and a particular 3D arrangement of the DNA in the nucleus of memory cells, allowing for rapid activation of these cells, according to a team of researchers from the Erasmus University Medical Center, the Centre for Genomic Regulation (CRG), and the Josep Carreras Leukaemia Research Institute.
According to new research published in Nature Biotechnology, artificial intelligence can predict on- and off-target behavior of CRISPR tools that target RNA rather than DNA.
A new editorial paper was published in Oncotarget's Volume 14 on June 21, 2023, entitled, "Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability."
Researchers from the Max Delbrück Center for Molecular Medicine in the Helmholtz Association in Berlin and the Centre for Genomic Regulation (CRG) in Barcelona have discovered how cells speed changes to their identity known as “cell fate conversion.”
Researchers at the Josep Carreras Leukaemia Research Institute, led by Dr. Manel Esteller, have discovered a key epigenetic alteration that anticipates the clinical course of liver cancer.
Helicobacter pylori is a common and deadly spiral-shaped bacteria.
Despite the astounding advances made in understanding the biologic underpinnings of cancer, many cancers are missing obvious genetic drivers.
Recent research from Temple University’s Lewis Katz School of Medicine and the University of Nebraska Medical Center demonstrates that gene-editing therapy aimed at two targets - HIV-1, the virus that causes AIDS, and CCR5, the co-receptor that aids the virus getting into cells—can effectively eliminate HIV infection.
Scripps Research scientists have developed a new strategy for identifying small molecules that can change the function of proteins, offering a promising path for discovering targeted drugs.
Researchers have developed a new method to distinguish between cancerous and healthy stem cells and progenitor cells from samples of patients with acute myeloid leukemia (AML), a disease driven by malignant blood stem cells that have historically been difficult to identify.